title: US Food and Drug Administration warning about the risk of drug reaction with eosinophilia and systemic symptoms with ziprasidone.
authors.affiliation: vicky.chan@fda.hhs.gov.
authors.forename: Vicky C
authors.initials: VC
authors.lastname: Chan
authors.forename: Lois
authors.initials: L
authors.lastname: La Grenade
authors.forename: Ida-Lina
authors.initials: IL
authors.lastname: Diak
authors.forename: Robert L
authors.initials: RL
authors.lastname: Levin
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D014150:Antipsychotic Agents / Q000009:adverse effects*; D063926:Drug Hypersensitivity Syndrome / Q000453:epidemiology*; D006801:Humans; D010879:Piperazines / Q000009:adverse effects*; D013844:Thiazoles / Q000009:adverse effects*; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D013844:Thiazoles; C092292:ziprasidone